Humacyte (HUMA) Scheduled to Post Quarterly Earnings on Friday

Humacyte (NASDAQ:HUMAGet Free Report) will be issuing its quarterly earnings data before the market opens on Friday, March 22nd. Analysts expect the company to announce earnings of ($0.25) per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Humacyte Trading Down 0.6 %

Shares of HUMA opened at $3.49 on Wednesday. The company has a quick ratio of 6.79, a current ratio of 6.79 and a debt-to-equity ratio of 0.46. Humacyte has a 12-month low of $1.96 and a 12-month high of $5.60. The firm has a market capitalization of $361.48 million, a PE ratio of -4.01 and a beta of 1.53. The stock’s fifty day simple moving average is $3.46 and its 200-day simple moving average is $3.00.

Analysts Set New Price Targets

HUMA has been the topic of several analyst reports. Benchmark cut their target price on Humacyte from $16.00 to $15.00 and set a “buy” rating on the stock in a research note on Wednesday, December 27th. HC Wainwright initiated coverage on Humacyte in a research report on Monday, December 11th. They issued a “buy” rating and a $6.00 price objective for the company.

Check Out Our Latest Research Report on Humacyte

Hedge Funds Weigh In On Humacyte

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its position in Humacyte by 13.2% during the second quarter. BlackRock Inc. now owns 4,304,505 shares of the company’s stock worth $12,311,000 after purchasing an additional 501,265 shares during the period. Vanguard Group Inc. boosted its position in Humacyte by 3.5% during the fourth quarter. Vanguard Group Inc. now owns 3,123,266 shares of the company’s stock worth $8,870,000 after purchasing an additional 104,299 shares during the period. Geode Capital Management LLC boosted its position in shares of Humacyte by 4.6% in the second quarter. Geode Capital Management LLC now owns 1,101,967 shares of the company’s stock valued at $3,152,000 after acquiring an additional 48,034 shares during the period. State Street Corp boosted its position in shares of Humacyte by 57.3% in the second quarter. State Street Corp now owns 1,039,280 shares of the company’s stock valued at $2,972,000 after acquiring an additional 378,485 shares during the period. Finally, Northern Trust Corp boosted its position in shares of Humacyte by 9.0% in the fourth quarter. Northern Trust Corp now owns 565,107 shares of the company’s stock valued at $1,605,000 after acquiring an additional 46,521 shares during the period. 27.36% of the stock is owned by institutional investors.

Humacyte Company Profile

(Get Free Report)

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs).

Further Reading

Earnings History for Humacyte (NASDAQ:HUMA)

Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.